Cargando…

An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese

Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Menglin, Yang, Jin, Yang, Linlin, Wang, Lina, Wang, Ting, Han, Shengna, Cheng, Ye, Chen, Zihua, Su, Yu, Zhang, Lirong, Yang, Fanping, Chen, Sheng-an, Zhang, Jin, Xiong, Hao, Wang, Lanting, Zhang, Zhen, Ma, Li, Luo, Xiaoqun, Xing, Qinghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404721/
https://www.ncbi.nlm.nih.gov/pubmed/37554438
http://dx.doi.org/10.1016/j.isci.2023.107391
_version_ 1785085360439558144
author Jiang, Menglin
Yang, Jin
Yang, Linlin
Wang, Lina
Wang, Ting
Han, Shengna
Cheng, Ye
Chen, Zihua
Su, Yu
Zhang, Lirong
Yang, Fanping
Chen, Sheng-an
Zhang, Jin
Xiong, Hao
Wang, Lanting
Zhang, Zhen
Ma, Li
Luo, Xiaoqun
Xing, Qinghe
author_facet Jiang, Menglin
Yang, Jin
Yang, Linlin
Wang, Lina
Wang, Ting
Han, Shengna
Cheng, Ye
Chen, Zihua
Su, Yu
Zhang, Lirong
Yang, Fanping
Chen, Sheng-an
Zhang, Jin
Xiong, Hao
Wang, Lanting
Zhang, Zhen
Ma, Li
Luo, Xiaoqun
Xing, Qinghe
author_sort Jiang, Menglin
collection PubMed
description Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗13:01 (odds ratio [OR]: 4.50; 95% confidence interval [CI]: 1.15–17.65; p = 0.043), HLA-B∗13:02 (OR: 6.14; 95% CI: 1.73–21.76; p = 0.0072), and serotype B13 (OR: 17.73; 95% CI: 3.61–86.95; p = 4.85 × 10(−5)) in patients with LEV-SCARs were significantly higher than those of levofloxacin-tolerant individuals. Molecular docking analysis suggested that levofloxacin formed more stable binding models with HLA-B∗13:01 and HLA-B∗13:02 than with non-risk HLA-B∗46:01. Mass spectrometry revealed that nonapeptides bound to HLA-B∗13:02 shifted at several positions after exposure to levofloxacin. Prospective screening for serotype B13 (sensitivity: 83%, specificity: 78%) and alternative drug treatment for carriers may significantly decrease the incidence of LEV-SCARs.
format Online
Article
Text
id pubmed-10404721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104047212023-08-08 An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese Jiang, Menglin Yang, Jin Yang, Linlin Wang, Lina Wang, Ting Han, Shengna Cheng, Ye Chen, Zihua Su, Yu Zhang, Lirong Yang, Fanping Chen, Sheng-an Zhang, Jin Xiong, Hao Wang, Lanting Zhang, Zhen Ma, Li Luo, Xiaoqun Xing, Qinghe iScience Article Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗13:01 (odds ratio [OR]: 4.50; 95% confidence interval [CI]: 1.15–17.65; p = 0.043), HLA-B∗13:02 (OR: 6.14; 95% CI: 1.73–21.76; p = 0.0072), and serotype B13 (OR: 17.73; 95% CI: 3.61–86.95; p = 4.85 × 10(−5)) in patients with LEV-SCARs were significantly higher than those of levofloxacin-tolerant individuals. Molecular docking analysis suggested that levofloxacin formed more stable binding models with HLA-B∗13:01 and HLA-B∗13:02 than with non-risk HLA-B∗46:01. Mass spectrometry revealed that nonapeptides bound to HLA-B∗13:02 shifted at several positions after exposure to levofloxacin. Prospective screening for serotype B13 (sensitivity: 83%, specificity: 78%) and alternative drug treatment for carriers may significantly decrease the incidence of LEV-SCARs. Elsevier 2023-07-13 /pmc/articles/PMC10404721/ /pubmed/37554438 http://dx.doi.org/10.1016/j.isci.2023.107391 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Jiang, Menglin
Yang, Jin
Yang, Linlin
Wang, Lina
Wang, Ting
Han, Shengna
Cheng, Ye
Chen, Zihua
Su, Yu
Zhang, Lirong
Yang, Fanping
Chen, Sheng-an
Zhang, Jin
Xiong, Hao
Wang, Lanting
Zhang, Zhen
Ma, Li
Luo, Xiaoqun
Xing, Qinghe
An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title_full An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title_fullStr An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title_full_unstemmed An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title_short An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
title_sort association study of hla with levofloxacin-induced severe cutaneous adverse drug reactions in han chinese
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404721/
https://www.ncbi.nlm.nih.gov/pubmed/37554438
http://dx.doi.org/10.1016/j.isci.2023.107391
work_keys_str_mv AT jiangmenglin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yangjin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yanglinlin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wanglina anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wangting anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT hanshengna anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chengye anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chenzihua anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT suyu anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhanglirong anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yangfanping anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chenshengan anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhangjin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT xionghao anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wanglanting anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhangzhen anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT mali anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT luoxiaoqun anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT xingqinghe anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT jiangmenglin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yangjin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yanglinlin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wanglina associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wangting associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT hanshengna associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chengye associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chenzihua associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT suyu associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhanglirong associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT yangfanping associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT chenshengan associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhangjin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT xionghao associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT wanglanting associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT zhangzhen associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT mali associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT luoxiaoqun associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese
AT xingqinghe associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese